General
Preferred name
GABAPENTIN ENACARBIL
Synonyms
gabapentin-enacarbil ()
Gabapentin encarbil ()
GSK1838262 ()
Horizant ()
XP13512 ()
XP-13512 ()
ASP8825 ()
XP 13512 ()
ASP-8825 ()
Gsk-1838262 ()
P&D ID
PD047336
CAS
478296-72-9
Tags
available
prodrug
drug
Approved by
FDA
First approval
2011
Drug Status
investigational
approved
Drug indication
Alcohol dependence
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Since gabapentin enacarbil is a prodrug of gabapentin, it's physiological effects are the same as gabapentin. Concerning PHN, gabapentin prevents allodynia and hyperalgesia.;
METABOLISM
Gabapentin enacarbil does not interact with any of the major cytochrome P450 ; enzymes.
DESCRIPTION
Gabapentin enacarbil is a prodrug of gabapentin. It exhibits increased bioavailability compared to gabapentin.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
10
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
JUMP-Target 1 Compound Set
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
31
Molecular Weight
329.18
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
1
Aromatic Ring Count
0
cLogP
2.68
TPSA
101.93
Fraction CSP3
0.81
Chiral centers
1.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CACNB4
Therapeutic Class
Neurology Agents
Source data
